Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Bolsas y Mercados Espanoles  >  Grifols, S.A.    GRF   ES0171996087

GRIFOLS, S.A.

(GRF)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Grifols S A : closes the acquisition of Green Cross fractionation plant in Canada and 11 plasma centers in the U.S.

10/02/2020 | 04:17am EST

Barcelona - Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and one of world's leading producers of plasma-derived medicines, today announced the closing of its transaction with the South Korean firm, GC Pharma (Group) to acquire a plasma fractionation plant, an immunoglobulin and an albumin purification plants in Montreal (Canada) for US$370 million, and, in a separate transaction, 11 plasma collection centers in the United States property of Green Cross for US$90 million.

This acquisition aligns with Grifols' international sustainable growth strategy, whose core objectives include increasing the company's supply of plasma and reinforcing its global expansion.

This strategic acquisition will strengthen Grifols' presence in Canada, building on a legacy of partnership in Canada's blood system. For more than three decades, Grifols has been a fractionator of Canadian plasma under contract manufacturing services, providing trusted plasma-derived medicines for Canadian patients and their healthcare providers.

As Víctor Grífols Deu, co-CEO of Grifols, notes, "This deal reflects our long-term vision and strategy of sustainable growth, and wholly aligns with our commitment to continue helping countries reach self-sufficiency of life-sustaining plasma-derived medicines, which are critical for patients who need them."

The transaction will also contribute to Grifols' international expansion by strengthening its presence in North America, since Canada is a market with one of the highest rates of plasma consumption per capita in the world and one with significant growth potential.

According to Raimon Grífols Roura, co-CEO of Grifols, "The addition of 11 U.S.-based plasma centers will reinforce our leadership and competitive advantages provided by our plasma-center network. By increasing our plasma collection and fractionation capacity, we are able to continue ensuring that patients worldwide have safe and secure access to these life-saving plasma-derived medicines."

In recent years, Grifols has forged a solid network of 300 plasma centers across the U.S. and Germany in order to diversify and expand its access to plasma. Grifols will continue its efforts to broaden this network through a combination of organic and inorganic growth, while working to attain greater operational efficiencies.

.

(C) 2020 M2 COMMUNICATIONS, source M2 PressWIRE

All news about GRIFOLS, S.A.
11/25GRIFOLS S A : Strategic alliance between Grifols and the Egyptian government to ..
AQ
11/24GRIFOLS S A : November 24, 2020Strategic alliance between Grifols and the Egypti..
PU
11/16GRIFOLS S A : The Dow Jones Sustainability Index recognizes Grifols as one of th..
AQ
11/16GRIFOLS S A : B. Braun Melsungen AG and Grifols form strategic alliance to offer..
AQ
11/13GRIFOLS S A : partners with TRC Healthcare to streamline intravenous compounding..
AQ
11/10GRIFOLS S A : consolidates its Hospital Division as a reference in innovative so..
AQ
11/09GRIFOLS S A : November 9, 2020Grifols consolidates its Hospital Division as a re..
PU
11/05GRIFOLS S A : 2020 third quarter earnings release
PU
11/05GRIFOLS S A : November 5, 2020Grifols continues delivering solid revenue and ear..
PU
11/05GRIFOLS, S.A. : 3rd quarter results
CO
More news
Financials
Sales 2020 5 402 M 6 436 M 6 436 M
Net income 2020 599 M 713 M 713 M
Net Debt 2020 6 256 M 7 454 M 7 454 M
P/E ratio 2020 27,5x
Yield 2020 1,62%
Capitalization 14 140 M 16 840 M 16 847 M
EV / Sales 2020 3,78x
EV / Sales 2021 3,51x
Nbr of Employees 24 000
Free-Float 80,2%
Chart GRIFOLS, S.A.
Duration : Period :
Grifols, S.A. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GRIFOLS, S.A.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 31,66 €
Last Close Price 23,82 €
Spread / Highest target 63,7%
Spread / Average Target 32,9%
Spread / Lowest Target 12,5%
EPS Revisions
Managers
NameTitle
Raimon Grifols Roura Joint Chief Executive Officer & Executive Director
Victor Grifols Deu Joint Chief Executive Officer & Executive Director
Víctor Grifols Roura Non-Executive Chairman
Alfredo Arroyo Guerra Chief Financial Officer & Vice President
Xavier Sueiras Gil Chief Information Technology Officer
Sector and Competitors
1st jan.Capitalization (M$)
GRIFOLS, S.A.-24.21%16 840
CSL LIMITED11.34%103 950
SAMSUNG BIOLOGICS CO.,LTD.84.53%48 002
BIOGEN INC.-18.53%37 201
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO.,LTD.138.48%29 065
ALEXION PHARMACEUTICALS, INC.13.83%26 903